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Review Article
ManagementandTreatmentofHepatocellularCarcinomawith
Immunotherapy: A Review of Current and Future Options
Shima Ghavimi, Tehila Apfel, Hamed Azimi, Alana Persaud and Nikolaos T. Pyrsopoulos*
Division of Gastroenterology and Hepatology, Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA
Abstract
With mortality rates of liver cancer doubling in the last
20 years, this disease is on the rise and has become the
fifth most common cancer in men and the seventh most
common cancer in women. Hepatocellular carcinoma (HCC)
represents approximately 90% of all primary liver cancers
and is a major global health concern. Patients with HCC can
be managed curatively with surgical resection or with liver
transplantation, if they are diagnosed at an early stage.
Unfortunately, most patients with HCC present with ad-
vanced stages of the disease and have underlying liver
dysfunction, which allows only 15% of patients to be eligible
for curative treatment. Several different treatment modal-
ities are available, including locoregional therapy radiofre-
quency ablation, microwave ablation, percutaneous ethanol
injection, trans-arterial chemoembolization, transarterial
radio-embolization, cryoablation, radiation therapy, stereo-
tactic radiotherapy, systemic chemotherapy, molecularly
targeted therapies, and immunotherapy. Immunotherapy
has recently become a promising method for inhibiting HCC
tumor progression, recurrence, and metastasis. The term
“Immunotherapy” is a catch-all, encompassing a wide range
of applications and targets, including HCC vaccines, adoptive
cell therapy, immune checkpoint inhibitors, and use of
oncolytic viruses to treat HCC. Immunotherapy in HCC is a
relatively safe option for treating patients with advanced
disease in the USA who are either unable to receive or failed
sorafenib/lenvatinib therapy and thus may offer an addi-
tional survival benefit for these patients. The purpose of this
review is to elaborate on some of the most recent advance-
ments in immunotherapy.
Citation of this article: Ghavimi S, Apfel T, Azimi H, Per-
saud A, Pyrsopoulos NT. Management and treatment of hep-
atocellular carcinoma with immunotherapy: A review of
current and future options. J Clin Transl Hepatol 2020;8
(2):168–176. doi: 10.14218/JCTH.2020.00001.
Introduction
With mortality rates of liver cancer doubling in the last 20 years,
this disease is on the rise and has become the fifthmost common
cancer inmen and the seventhmost common cancer in women.1
Currently, hepatocellular carcinoma (HCC) represents approxi-
mately 90% of primary liver cancers and is a major global
health concern.2 There are many risk factors responsible for
the development of HCC, such as viral infections, hereditary
hemochromatosis, non-alcoholic fatty liver disease, increased
alcohol-related liver disease, and cirrhosis, among others.3
HCC development is a complex process involving multiple
factors and pathways that lead to changes in gene expression,
immune interactions, and changes in the tumor microenviron-
ment that ultimately cause hepatocarcinogenesis.4
Screening for HCC in high-risk populations has become the
standard of care, requiring imaging with ultrasound, compu-
terized tomography, or magnetic resonance imaging every 6-
12 months.5 Laboratory tests, including mainly those for
alpha feto-protein, the lectin Lens culinaris agglutinin-bound
fraction of alpha feto-protein-3, and des-gamma-carboxy
prothrombin, are used in conjunction with imaging to estab-
lish the diagnosis.6,7 Multiphasic imaging modalities, such as
computerized tomography and magnetic resonance imaging,
are used for detection and diagnosis of HCC. Liver biopsy is
not necessary once the Liver Imaging Reporting and Data
System (known as ‘Li-Rads’) has been deemed to be category
5, which is diagnostic for HCC.8
If a lesion is deemed to be HCC, the available options for
management are varied and depend on multiple factors,
including the number of lesions, their size, the presence of
extrahepatic spread, and the severity of the patient’s under-
lying liver disease.9 The recommendation from The European
Association for the Study of Liver panel of experts is to con-
sider the following four related aspects to determine treat-
ment options: tumor stage, degree of liver function
impairment, general condition of the patient, and treatment
efficacy.10,11 Fig. 1 depicts the Barcelona Clinic Liver Cancer
system, which is one of the most commonly used algorithms
to assist in determining treatment options based on the afore-
mentioned factors.11–14 To summarize, patients diagnosed as
stage 0, with very early HCC, are ideal candidates for ablation
or resection.11 Patients who are deemed to be stage A, with
early HCC, are candidates for radical therapies, including hep-
atoma resection, liver transplantation, or interventional radi-
ology procedures.10,11 Patients at stage B, with intermediate
HCC, may benefit from chemoembolization.10,11 Patients at
stage C, who already have advanced HCC, are only candi-
dates for systemic therapy if their performance status is
acceptable; otherwise, they are managed with the best
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supportive care available.11 Approximately 85% of patients
with HCC are diagnosed at later stages or have underlying
liver dysfunction, limiting their treatment options.9 These
patients usually have a very poor prognosis, with survival of
less than 1 year.15 In patients treated with resection or abla-
tion, tumor recurrence (both true recurrence due to dissem-
ination and de novo tumors) is unfortunately common and is
seen in up to 70% of patients 3-5 years after treatment.16
Liver transplantation is an important treatment modality
for patients who meet Milan criteria (a single HCC nodule of 2-
5 cm or 3 HCC nodules each #3 cm in diameter) or who
undergo down-staging of their tumors to be within the Milan
criteria.17–20 Studies have shown that patients who met Milan
criteria and received a liver transplant had survival rates
exceeding 70% at 5 years, with recurrence in less than 15%
of patients.21 Approximately 30-40% of patients on the liver
transplantation waitlist are patients who have received model
for end-stage liver disease (MELD) exception points for
HCC.22 They receive these points 6 months after listing and
then receive an incremental increase in their MELD points
every 3 months until the maximum MELD exception point
allowance is reached (that being 34).23,24 MELD exception
points give patients an increased chance of receiving a liver
but they do not guarantee a liver to all listed patients. There-
fore, additional treatments for HCC are greatly needed.
In 1891, the surgeon William Coley injected streptococcal
organisms into a patient with inoperable osteosarcoma,
successfully stimulating the immune system and leading to
tumor regression and thus fathering the field of immunother-
apy.25 Since then, there have beenmany achievements in use
of immunotherapy to fight cancer and in the development of a
broad range of therapeutic applications, including the use of
gene therapy, oncolytic viruses, cytokines, adoptive cell
therapy, vaccines, and immune checkpoint inhibitors to fight
cancer.25
Immunotherapy has recently become a new promising
method for inhibiting HCC tumor progression, recurrence,
and metastasis.26,27 “Immunotherapy” is a catch-all term,
encompassing a wide range of applications and targets,
including HCC vaccines, adoptive cell therapy (ACT),
immune checkpoint inhibitors, and use of oncolytic viruses
to treat HCC. These approaches have often shown initial
success in treating other types of cancers, with potential to
be similarly successful in treating HCC. In this review, we will
discuss some of the most recent advancements in immuno-
therapy for HCC.
Tumor immunology
Research has shown that cancer cells are able to escape from
immunological surveillance and suppress the activation of
immunocompetent cells (immune suppression), thereby
allowing for their continued growth.27 Cancer immunoediting
is a proposed mechanism to explain how tumors evade the
Fig. 1. Hepatocellular carcinoma treatment in patients diagnosed with hepatocellular carcinoma.
Modified Barcelona Clinic Liver Cancer (BCLC) staging and treatment strategy: The BCLC system recommends pathways for treatment based on
prognostic stages. The stage is determined by the number of lesions and their size, evidence of extrahepatic spread/portal invasion, performance
status (ps), preserved liver function, and evidence of decompensated liver disease (usually determined by the Child-Pugh classification or the model
for end-stage liver disease score). As noted, there are multiple treatment options, including resection, transplantation, chemoembolization, ablation,
systemic therapy or best support care, which is essentially palliative care. Survival is predicted based on what initial therapy was chosen.11
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immune system, consisting of three sequential phases: elim-
ination, equilibrium, and escape.28 In the elimination phase,
innate and adaptive immunity work together to destroy
developing HCC long before it becomes clinically apparent.
If this phase is not successful, the cancer cell variant may
then enter the equilibrium phase, in which its growth is pre-
vented by immunologic mechanisms.28 Important players
from the adaptive immune system, T cells, interleukin-12,
and interferon-a suppress the growth of cancer cells during
this phase.28 The equilibrium state may represent an end
stage of the cancer immunoediting process, creating occult
cancers that do not grow any larger and are clinically insignif-
icant during the lifetime of the host.28 However, because of
this constant immune selection pressure placed on “geneti-
cally unstable” tumor cells, new cell variants can become (1)
unrecognizable to the adaptive immune system, due to
antigen loss and defects in antigen processing or presenta-
tion, (2) insensitive to immune effector mechanisms, or (3)
able to induce an immunosuppressive state within the tumor
microenvironment.28 These tumor cells may then enter the
escape phase, in which their growth is no longer controlled
by the immune system and clinically significant disease
develops.28
An important escape mechanism allows tumor cells to up-
regulate their own expression of immune checkpoint mole-
cules, including the programmed cell death-1 (PD-1) protein
that binds to the programmed death-ligand 1 (PD-L1) and
stimulates peripheral T cell depletion.29 Another important
checkpoint molecule, cytotoxic T lymphocyte-associated
protein 4 (CTLA-4), is found on the surface of T cells and
can be activated by tumor cells, leading to down-regulation
of T cells.27 Interestingly, initial studies done by Duffy et al.30
in 2017 showed that in liver biopsies of patients treated with
tremeliomumab, an anti-CTLA-4 antibody, there was an
increase in cytotoxic T cells, demonstrating that treatment
with such molecules increased activity of the immune
system. Monoclonal antibodies to PD-1, PD-L1, and CTLA-4
are called immune checkpoint inhibitors and have become an
important part of immunotherapy treatments for many
cancers, including melanoma, non-small cell lung cancer,
and colorectal cancer, and are now emerging as valuable
treatments in HCC.29,31
Checkpoint inhibitors
Checkpoint inhibitors are currently the most successful
immunotherapy treatment for HCC.27 As noted in Tables 1
and 2, and illustrated in Fig. 2, there are multiple novel treat-
ments available and many active clinical trials investigating
further checkpoint inhibitors.
Nivolumab
Promising results were reported in 2017 from the Checkmate
040 phase I/II trial which looked into survival rates for
nivolumab, an anti-PD-1 antibody, used in the treatment of
advanced HCC.32 A dose-escalation and expansion phase was
implemented in patients who met strict inclusion criteria, with
clinically less severe underlying liver dysfunction.32 Treat-
ment in 262 patients yielded an acceptable safety profile
and promising efficacy, and based on these results, the
Food and Drug Administration fast-tracked the approval of
nivolumab for the treatment of patients diagnosed with HCC
who had been previously treated with sorafenib.27 Another
small phase II trial investigating nivolumab alone versus
nivolumab and ipilimumab is currently underway, with pre-
liminary results demonstrating a good safety profile and
that treatment does cause delay to surgical resection.33















Tremelimumab (21) Anti-CTLA-4 23.8 17.6/76.4 6.48/NR 8.2 49
Duffy 2017 Tremelimumab +
subtotal ablation (32)
Anti-CTLA-4 65.6 26.3/NR 7.4/NR 12.3 30
El-Khoueiry
2017
Nivolumab (80) Anti-PD-1 0 22.5/62.5 NR/NR 28.6 32
El-Khoueiry
2017
Nivolumab (182) Anti-PD-1 100 18.7/62.6 NR/NR 15.6 32
Wainberg
2017
Durvalumab (40) Anti-PD-L1 92.5 10/32.5 NR/2.7 13.2 73




75 25/57.5 NR/NR NR 74
Zhu 2018 Pembrolizumab
(104)
Anti-PD-1 100 17.3/61.5 NR/4.9 12.9 37
Ikeda 2018 Pembrolizumab +
lenvatinib (30)
Anti-PD-1 13.3 42.3/100 NR/9.7 NR 42




0 65/96% NR/NR NR 51
Abbreviations: CTLA–4, cytotoxic T lymphocyte–associated protein 4; DCR, disease control rate; IT, immunotherapy; NR, not reported; ORR, overall response rate; OS,
overall survival; PD–1, programmed cell death-1; PD–L1, programmed cell death 1-ligand 1; PFS, progression–free survival; TTP, time to progression.
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Checkpoint 459 is a phase III study comparing nivolu-
mab and sorafenib as first-line treatment for HCC.34 Pre-
liminary data was released in June 2019, which showed
that the overall survival failed to meet statistical signifi-
cance (hazard ratio of 0.85; 95% confidence interval,
0.72-1.02; p=0.0752). The data reportedly did show a
trend towards an overall survival improvement with nivolu-
mab versus sorafenib.34 At the time of this publication,
Bristol-Myers Squibb has not yet released the full data.34
There are also currently other ongoing trials investigating
nivolumab as a single agent in CheckMate-9DX and also in
combination with ipilimumab for previously-treated
patients with HCC.26,35,36
Pembrolizumab
While nivolumab was investigated as a first-line treatment
option for HCC, another anti-PD-1 antibody, pembrolizumab,
is being developed as a second-line treatment after initial
treatment with tyrosine kinase inhibitors have failed or were
not tolerable.27 In a phase II trial, patients with advanced
liver cancer who were sorafenib-refractory, sorafenib-intoler-
ant, or sorafenib-naïve received one standard dose of pem-
brolizumab.37 Interval results showed an 18% response rate
and a 12.9 month median survival period.37 In November of
2018, the Food and Drug Administration granted an acceler-
ated approval for pembrolizumab to be used in treatment of
patients with HCC who have been previously treated with
sorafenib.37 However, in the follow-up, phase III
KEYNOTE-240 trial, pembrolizumab failed to meet the
primary endpoints for both overall survival and progres-
sion-free survival when pembrolizumab was compared to
placebo and best supportive care in HCC patients that had
already failed systemic therapy.38 While pembrolizumab com-
pared with placebo did show improvement in overall survival
and progression-free survival, the improvement was not
deemed statistically significant (overall survival:hazard ratio,
0.78; 95% confidence interval, 0.611-0.998; p=0.0238; pro-
gression-free survival:hazard ratio, 0.78; 95% confidence
interval, 0.61-0.99; p=0.0219).38 Although disappointing,
this has not deterred other investigations of pembrolizumab
in HCC patients. In the UK, a phase II/III study is underway
investigating pembrolizumab as an adjunctive treatment to
trans-arterial chemoembolization (TACE) using doxorubicin
and gelatin sponges.27
An additional phaseIII study, KEYNOTE-394 (NCT03062358),
is currently evaluating and recruiting patients and is using the
same inclusion criteria as set in the Keynote-240 trial in hopes
of better outcomes in an Asian population.39
Tislelizumab
Tislelizumab, another anti-PD-1 antibody, is currently under
development by BeiGene.40 The safety of tislelizumab was
Table 2. Ongoing phase III trials testing immune checkpoint inhibitors in hepatocellular carcinoma





Nivolumab vs. placebo Anti-PD-1 Curative adjuvant NCT03383458 Recruiting Q1 2022
Nivolumab + TACE Anti-PD-1 Curative adjuvant NCT03143270 Recruiting Q1 2019
Nivolumab + TACE Anti-PD-1 Curative, adjuvant NCT03572582 Recruiting Q3 2022





Palliative, 1st-line NCT03298451 Recruiting Q1 2020
Atezolizumab + bevacizumab
vs. sorafenib
Anti-PD-L1 Palliative, 1st-line NCT03434379 Recruiting Q2 2021
Pembrolizumab vs. placebo Anti-PD-1 Palliative, 2nd-line NCT02702401 Active, not
recruiting
Q1 2019
Pembrolizumab + TACE Anti-PD-1 Curative, 2nd-line NCT03397654 Recruiting Q4 2019
Pembrolizumab vs. placebo Anti-PD-1 Palliative, 2nd-line NCT03062358 Recruiting Q4 2019
Pembrolizumab vs. best
supportive care
Anti-PD-1 Palliative, 2nd-line NCT02702401 Active, not
recruiting
Q4 2020
Tislelizumab vs. sorafenib Anti-PD-1 Curative, 1st-line NCT03412773 Recruiting Q4 2022
Atezolizumab + bevacizumab Anti-PD-L1 +
anti-VEGF
Curative, 1st-line NCT03434379 Recruiting Q2 2022
Ipilimumab + nivolumab Anti-CTLA-4 +
Anti-PD-1
Curative, adjuvant NCT03682276 Recruiting Q4 2022










Curative, adjuvant NCT03482102 Recruiting Q4 2025
Abbreviations: CTLA–4, cytotoxic T lymphocyte–associated protein 4; IT, immunotherapy; PD–1, programmed cell death-1; PD–L1, programmed cell death 1-ligand 1.
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established in an earlier phase I trial, with multiple different
solid cancers, including HCC.41 Currently, there is a multicen-
ter global phase III trial looking at tislelizumab versus sora-
fenib as first-line treatment for unreachable HCC that started
recruitment in 2017.27,40,42 This trial set survival rate as the
principal endpoint and was designed to validate that non-infe-
riority of tislelizumab compared to sorafenib (Table 2). No
interim data are currently available.
Camrelizumab
Camrelizumab is an anti-PD-1 antibody, for which a phase II/
III trial is currently underway in China, looking at patients
who failed to respond to systemic treatments or were intol-
erant to previous systemic treatments.27 Provisional results
from the phase II part was presented in 2018 at a meeting of
the European Society for Medical Oncology, demonstrated a
response rate of 13.8% (30/217) with a 6-month overall sur-
vival rate of 74.7%.27 It is notable that only two patients
(0.9%) experienced grade 5 treatment-related adverse
events, which in turn showed camrelizumab to have a suitable
toxicity profile.27 No interim date is available from the phase
III part. Currently, there is an ongoing phase II trial in China
looking at camrelizumab plus the FOLFOX4 regimen (consist-
ing of 5-fluorouracil, leucovorin, and oxaliplatin) for treat-
ment of advanced HCC and biliary tract cancers in patients
who failed systemic treatment.43 Interim results from
October 2018 were promising, with median progression-free
survival of 5.5 months; however, over 85% of patients had
severe treatment related side-effects.43
Durvalumab
Durvalumab is the only anti-PD-L1 antibody for HCC under
investigation currently.27 Cancer cells can avoid immune sur-
veillance by overexpressing PD-L1 and activating PD-L1/PD-1
signaling, which is observed in HCC tissues (Fig. 2).44,45 A
basic science study recently showed that inhibition of PD-L1
and DNA methyltransferase 1 (commonly known as DNMT1)
significantly suppressed the growth of sorafenib-resistant
HCC cells in vitro.46,47 This points to a possible novel treat-
ment option for sorafenib-resistant HCC.26,48 A phase I/II
trial looking at the safety of durvalumab monotherapy in
treating solid tumors showed durvalumab to have an accept-
able safety profile and to be promising, with a 10% response
rate and a median survival time of 13.2 months for the HCC
cohort.26 A phase III trial that started in 2017 is currently
underway looking at durvalumab plus tremelimumab combi-
nation therapy as a first-line treatment for patients with
advanced HCC; however, currently there are no interim
results available.27
Tremelimumab
Tremelimumab is another anti-CTLA-4 antibody under inves-
tigation for HCC.27 To date, remelimumab monotherapy has
been investigated for patients with HCC and chronic hepatitis
C.49 Results from the trial were promising, and showed that of
the 21 patients enrolled, there was a partial response rate of
17.6% and a median time to progression of 6.48 months.27
Overall, the treatment was very well tolerated, with minimal
toxicities, such as transient elevation of transaminases,
noted.27 A phase I/II trial investigating the combination of
tremelimumab plus interventional procedures, such as radio-
frequency ablation, TACE, and cryoablation, for non-resetta-
ble HCC patients is currently underway in the USA.30 Initial
results show no dose limiting toxicities and of the 19 patients
that were suitable for evaluation, 5 (26.3%) achieved partial
responses outside of the areas treated with TACE or abla-
tion.27 The median progression-free survival period was 7.4
months, with the median survival period of 12.3 months.25
Combined targeted therapy
Atezolizumab + bevacizumab
Novel combination treatment with atezolizumab, an anti-PDL-
1 antibody, and bevacizumab, an anti-vascular endothelial
growth factor (VEGF) therapy, is under investigation for
treatment of advanced HCC and has shown to be effective
in combination when treating other cancers.50 HCC tumors
over-express VEGF and PD-L1 and there is evidence of
increased vascularity, which makes it a good target for this
combination therapy that targets both sites.51–53 Two global
I/Ib studies showed promising results when looking at this
combo in patients with unrespectable HCC who had not
received prior systemic therapy but some of who received
TACE and/or radiotherapy.54 Data from the non-randomized
arm of 119 patients showed an objective response rate of
36% (95% confidence interval, 26–46), with 12% of enrolled
patients having complete response to treatment and a
median overall survival of 17.1 months.54
The second arm of the study randomized the same patient
population to atezolizumab and bevacizumab versus atezoli-
zumab monotherapy.54 Of those who received the
Fig. 2. Mechanism of action of checkpoint inhibitors under investigation
for hepatocellular carcinoma treatment.
Hepatocellular carcinoma (HCC) tumor cells can up-regulate ex-
pression of programmed cell death-1, PD-1, which binds the pro-
grammed death-ligand 1, PD-L1, and stimulates peripheral T cell
depletion.29 They can also activate cytotoxic T lymphocyte-associated
protein-4 (CTLA-4), found on the surface of T cells and leading to
down-regulation of T cells.27 Ipilimumab and tremelimumab bind to
and inactivate CTLA-4, preventing its activation. PD-1-PD-L1 binding
may be prevented by therapeutically blocking either PD-1 (nivolumab,
pembrolizumab, tislelizumab, and camrelizumab) or PD-L1 (durvalu-
mab and atezolizumab).
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combination therapy, 20% had confirmed responses and 47%
had stable disease, compared to 17% and 32% of patients,
respectively, in the atezolizumab monotherapy group.54 This
accounted for the 0.55 hazard ratio (80% confidence interval,
0.40–0.74; p=0.0108) reported.54 Additionally, median pro-
gression-free survival in the combination arm was 5.6 months
compared to 3.4 months in the monotherapy group.55
There were increased grade 3/4 adverse events in the
combination group (34% vs. 14%) with the most common
adverse events being proteinuria, fatigue, and rash.54 Based
on data that showed an objective response rate of 36% (95%
confidence interval, 26–46), the Food and Drug Administra-
tion granted Breakthrough Therapy Designation for atezolizu-
mab/bevacizumab combination therapy to be a fist-line
therapy for advanced or metastatic HCC.55 In addition, enroll-
ment for a new phase III study, IMbrave150 (NCT03434379),
has completed enrollment and will be comparing atezolizu-
mab/bevacizuma versus sorafenib in unresectable HCC
patients.55
Ipilimumab + nivolumab
Ipilimumab is an anti-CTLA-4 antibody and multiple studies
have recently investigated its use in combination with nivo-
lumab. In the USA, the CheckMate040 trial results were
recently published (NCT01658878).56 The trial enrolled HCC
patients who had failed treatment with sorafenib and random-
ized the patients to receive one of three different protocols of
ipilimumab plus nivolumab. The combined treatment report-
edly showed an acceptable safety profile, with an objective
response rate that was twice that of nivolumab monotherapy
(31% compared to 14%) and having median overall survival
of 18 months.56
In the UK, the PRIME-HCC clinical trial is underway,
assessing the efficacy of combination treatment pre-opera-
tively with nivolumab and ipilimumab in HCC patients for
whom liver resection is planned.27 Participants will receive
two doses of nivolumab and a single dose of ipilimumab in
the weeks before their surgery. This is a single-arm, open-
label study to be conducted in 32 patients at a small
number of UK hospitals. The study has two parts. Part 1 will
confirm, in a small number of patients, that the treatment
regimen is safe and does not result in delay to liver resection,
while Part 2 will expand the number of patients studied and
assess survival over 2 years post-resection. The decision to
proceed to Part 2 will be taken with advice from an independ-
ent, expert committee.27
SHR-1210 + Apatinib
The combination of SHR-1210, a novel anti-PD-1 antibody,
and apatinib, a tyrosine kinase inhibitor selectively acting on
VEGF receptor 2, is currently being investigated.27 A phase 1
trial was completed in 2018 and showed acceptable tolerabil-
ity of this combination and a response rate of 38.9%, with a
median progression-free survival of 7.2 months for the 18
patients with HCC.44 Overall, adverse events were relatively
tolerable, with only one patient discontinuing the treatment
due to treatment-related grade 3 hyperbilirubinemia.44 Cur-
rently, a phase II trial is underway in the USA, comparing this
combination to systemic chemotherapy in advanced HCC.57
No results are available currently.
Other targets in immunotherapy
ACT is a new approach to look for treatments that allow a
patients’ own lymphocytes to attack cancer cells.58,59 Adop-
tive immunotherapy for HCC includes cytokine-induced killer
cells, tumor-infiltrating lymphocytes, natural killer cells, and
chimeric antigen receptor (CAR) T cells. The safety of ACT in
patients with HCC have been investigated in many preclinical
studies, thus laying a foundation for its clinical
applications.58,59
CAR-Tcell therapy, in particular, has been a very successful
novel method of treating CD19-positive hematological malig-
nancies, and its application has recently been considered in
the treatment of solid tumors, including HCC.33 Currently,
there are no clinical trials investigating CAR-T cell therapy
for HCC, as there have been many concerns about the drug
causing cytokine-release syndrome, which affects up to 90%
of patients and can cause cardiovascular, pulmonary, and
central nervous system complications.59–61 Additionally,
there is currently a lack of specific tumor antigens to target
in HCC, limited trafficking and penetration of CAR-T cells to
tumor sites, and an immunosuppressive tumor microenviron-
ment.33 To overcome these difficulties, numerous strategies
have been developed, including enhancing the selectivity of
CARs and controlling CAR-T activity.33 In a recent study by
Guo et al.,62 the investigators concluded that gene-edited
CAR T cells with PD-1 deficiency have stronger antitumor
activity than wild-type CAR T cells and future development
of CAR T cells with modified gene-editing may help improve
CAR T cell efficacy as a treatment for HCC.62 In another basic
research study, Li et al.63 demonstrated that GPC3-targeting
CAR Tcells, in particular CAR.hYP7, are a promising therapeu-
tic intervention for liver cancer that can be translated for
human use.63 There is hope that with further investigation
and clinical trials, CAR-T cell therapy will become a viable
option for HCC treatment.
Interferon monotherapy has also been explored as adju-
vant therapy, to both prevent tumor recurrence as well as to
inhibit development of HCC in patients with chronic hepatitis
B and C infections.64–66 According to a published report by Lai
et al.,67 interferon-a increased survival rates and encouraged
tumor regression in patients diagnosed with advanced HCC.
According to Obi et al.,68 16% of HCC patients with portal vein
invasion who received a combination of 5-flurouracil and
interferon-a treatment had complete response, while 36%
had a partial response, as interferon-a can induce apoptosis
and inhibit cell growth in HCC tumors.
Different than ACT, cell-mediated immunotherapy is a
novel approach that has been used to exploit the unique
pattern of proteins that are expressed specifically on tumor
cells as targets. Tumor-targeted antibodies are mutant or
aberrantly expressed antigens on the surface on cancer cells
and can be potential targets of the adaptive human immune
system.36 Tumor-targeted antibodies are being investigated
for HCC immunotherapy, with a focus on alpha feto-protein-
directed treatments.69 Another approach is to use oncolytic
viruses to attack HCC tumor cells.70–72 Theoretically, these
viruses can selectively replicate in tumor cells and cause
lysis without harming normal tissues.26 Oncolytic virother-
apy-mediated oncolysis not only leads to tumor regression
but also provides important immune responses. Most inves-
tigations into oncolytic virotherapy are currently in the pre-
clinical or early clinical stages but are promising.70
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Conclusions
Immunotherapy is a promising new frontier for HCC treat-
ment, with many novel new strategies currently under devel-
opment. The incidence of HCC is rapidly increasing, and it is a
major cause of morbidity and mortality both nationally and
internationally. Though HCC can be a devastating disease, the
best hope for prolonged survival is early screening and
diagnosis. Although there is some debate regarding the
ideal methods of surveillance, ultrasound with and without
alpha feto-protein every 6-12 months is generally accepted
as standard practice in the proper patient population. Cur-
rently, multiple therapeutic modalities are available and
research investigating innovative options is ongoing. Most
patients are best served in liver transplant centers, where a
multidisciplinary approach can take place under the guidance
of experienced transplant hepatologists and gastroenterolo-
gists. Advances in HCC prevention, detection, and treatments
have resulted in improved survival for a disease that was,
until recently, considered terminal. Randomized phase I-III
trials of nivolumab, atezolizumab, durvalumab, ipilimumab
and tislelizumab as monotherapy or combination therapy are
currently being conducted. However, there is still much to be
revealed regarding checkpoint inhibitors as well as immuno-
therapy involving gut microbiota and monocytes in the
peripheral blood, so clinical trials are necessary to determine
their full benefit. Immunotherapy and targeted molecular
therapies have personalized medical therapy, while improving
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